RxDoctor Payments Data

Christina Brown, DO

Internal Medicine · Benton, KYNPI 1598057549

Payments from drug & device makers

$1,418in general payments, 2019–2025

Across 81 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$283
  • Amgen$268
  • Astellas Pharma US Inc$246
  • Novartis$197
  • Pfizer$84
  • Lilly USA, LLC$48
  • plus $293 from 13 others

What the payments were for

  • Food & beverage$1,23487%
  • Education$18413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,418 in reported general payments places this provider in the 70th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$86
Medicare patients
11
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$117,071
EliquisApixaban93$94,975
JardianceEmpagliflozin57$53,716
MounjaroTirzepatide28$48,793
FarxigaDapagliflozin Propanediol34$39,299
JanuviaSitagliptin Phosphate24$33,835
TrulicityDulaglutide16$28,994
XareltoRivaroxaban14$22,359
Breo ElliptaFluticasone/Vilanterol33$20,701
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$19,948
Repatha SureclickEvolocumab21$17,358
Tresiba Flextouch U-200Insulin Degludec17$15,198
MyrbetriqMirabegron11$11,350
Tresiba Flextouch U-100Insulin Degludec24$10,885
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$10,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$283$119,186115 claims
PfizerEliquis$84$94,97593 claims
Lilly USA, LLCMounjaro, Trulicity$48$77,78744 claims
AstraZenecaFarxiga, Breztri Aerosphere$34$59,24659 claims
Boehringer IngelheimJardiance$17$53,71657 claims
MerckJanuvia$22$33,83524 claims
Johnson & JohnsonXarelto$17$22,35914 claims
GSKBreo Ellipta$33$20,70133 claims
Astellas Pharma US IncMyrbetriq$246$11,35011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Benton

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →